Aurobindo nabs bankrupt Natrol for $132.5M; Scots reject Roche's Perjeta as too costly;

@FiercePharma: Top-read in #pharma #manufacturing Tues: Dr. Reddy's, Endo benefit from Ranbaxy manufacturing shortfalls. More | Follow @FiercePharma

@EricPFierce: Cadilia gets slapped with #FDA warning for not following up on complaints about stinking APIs. More | Follow @EricPFierce

@CarlyHFierce: Mylan visits Disney Parks for a little EpiPen marketing magic. More | Follow @CarlyHFierce

> India's Aurobindo Pharma won a bankruptcy auction to buy the California-based nutritional supplements company Natrol for $132.5 million. Report

> After Scotland's cost-effectiveness watchdogs refused to approve Roche's ($RHHBY) new breast cancer drug Perjeta, patient groups started agitating for a price cut. Report

> Pfizer ($PFE) launched an authorization system for its products in Malaysia, to help patients separate authentic products from counterfeits. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: With fresh infusion of cash in tow, Thync rolls out wearable, noninvasive device to elevate mood. Article | Follow @FierceMedDev

@VarunSaxena2: Aethlon to begin U.S. testing for its Ebola treatment device by year end. More | Follow @VarunSaxena2

@EmilyWFierce: Mark your calendars: EU Commission will decide by Nov. 28 whether or not to approve $MDT's $43B deal for $COV. More  | Follow @EmilyWFierce

> Medtronic borrows $16B to cover rising costs of Covidien deal. Article

> FDA clears first patient-specific spinal rod. More

Biotech News

@FierceBiotech: $AMGN and $AZN psoriasis drug beats blockbuster Stelara ($JNJ) in head-to-head trial. Report | Follow @FierceBiotech

@JohnCFierce: Servier gambling up to $1B-plus on Intarcia's PhIII diabetes drug/device. News | Follow @JohnCFierce

@DamianFierce: Hep C market share optimism has $ABBV up. Also, cab ads. Picture | Follow @DamianFierce

> Takeda's Millennium re-ups with Presage on cancer drug combo effort. Item

> Blueprint Medicines banks $50M for its personalized take on cancer. News

> Fujifilm says its flu drug is an Ebola solution in waiting. Article

Drug Delivery News

> Drug-loaded milk could offer oral HIV/AIDS prevention to children. Story

> Alnylam adds two RNAi programs to its hepatitis pipeline. Article

> Arrowhead's midstage hep B data shows promise for RNA-based 'functional cure.' News

> FDA clears syringe that prevents needlestick injuries. News

> Nasal spray for migraines under development. Story

Diagnostics News

> Study: Myriad skin cancer Dx shows reduction in indeterminate diagnoses. More

> GE Healthcare lends imaging tech to Takeda for Dx partnership. Story

> Quest CEO says 'no' to CRO. Report

> Study: Myriad skin cancer Dx shows reduction in indeterminate diagnoses. More

> GE Healthcare lends imaging tech to Takeda for Dx partnership. Item

> Scientists developing machine-based algorithm for heart failure and emphysema Dx. Article

Pharma Marketing News

> Under siege by Biogen's new long-acting Eloctate, Baxter's Advate stands its ground. Report

> Missing the old pharma swag? Take a trip down memory lane. Article

> Will GLP market growth save Novo's Victoza from Lilly's new Trulicity? More

> Contrave demand swamps Takeda's direct-delivery discount program. Story

> Mylan visits Disney Parks for a little EpiPen marketing magic. Article

And Finally... Former Apple ($AAPL) CEO John Sculley grabbed a stake in the telemedicine company MDLive, saying he sees online services "going mainstream" in coming years. Report

Suggested Articles

Stephen Hahn, an oncologist who served as the chief medical officer for the MD Anderson Cancer Center, has secured Senate confirmation as FDA head.

As BMS searches for bright spots in its Opdivo-chemo combo fail from June, it’s zeroing in on squamous lung cancer patients who seemed to benefit.

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.